A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Tal Noy-Porat, Efi Makdasi, Ron Alcalay, Adva Mechaly, Yinon Levy, Adi Bercovich-Kinori, Ayelet Zauberman, Hadas Tamir, Yfat Yahalom-Ronen, Ma’ayan Israeli, Eyal Epstein, Hagit Achdout, Sharon Melamed, Theodor Chitlaru, Shay Weiss, Eldar Peretz, Osnat Rosen, Nir Paran, Shmuel Yitzhaki, Shmuel C. Shapira, Tomer Israely, Ohad Mazor () and Ronit Rosenfeld ()
Additional contact information
Tal Noy-Porat: Israel Institute for Biological Research
Efi Makdasi: Israel Institute for Biological Research
Ron Alcalay: Israel Institute for Biological Research
Adva Mechaly: Israel Institute for Biological Research
Yinon Levy: Israel Institute for Biological Research
Adi Bercovich-Kinori: Israel Institute for Biological Research
Ayelet Zauberman: Israel Institute for Biological Research
Hadas Tamir: Israel Institute for Biological Research
Yfat Yahalom-Ronen: Israel Institute for Biological Research
Ma’ayan Israeli: Israel Institute for Biological Research
Eyal Epstein: Israel Institute for Biological Research
Hagit Achdout: Israel Institute for Biological Research
Sharon Melamed: Israel Institute for Biological Research
Theodor Chitlaru: Israel Institute for Biological Research
Shay Weiss: Israel Institute for Biological Research
Eldar Peretz: Israel Institute for Biological Research
Osnat Rosen: Israel Institute for Biological Research
Nir Paran: Israel Institute for Biological Research
Shmuel Yitzhaki: Israel Institute for Biological Research
Shmuel C. Shapira: Israel Institute for Biological Research
Tomer Israely: Israel Institute for Biological Research
Ohad Mazor: Israel Institute for Biological Research
Ronit Rosenfeld: Israel Institute for Biological Research

Nature Communications, 2020, vol. 11, issue 1, 1-7

Abstract: Abstract The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18159-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18159-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18159-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().